The Medicines Patent Pool (MPP) has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 22 generic manufacturers and product developers have now signed MPP sublicensing agreements.

Overview of all licensing and sublicensing agreements

Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 26 million patient-years of HIV and hepatitis C products, saving international procurers USD 1.23 billion (Jan. 2012-June 2019).

PPT presentations, highlighting progress of MPP’s generic partners in developing, manufacturing and supplying MPP-licensed medicines, are available for:

(Last update: October 2019 – data as of June 2019)

[WHO-PQ] Prequalification from the World Health Organization | [USFDA] U.S. Food and Drug Administration | [ERP] Expert Review Panel led by the Global Fund

Last update of the table: January 2020 (data as of September 2019)

This website uses cookies to ensure you get the best experience on our website. Learn More